Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (9319)	3/22/1999 5:57:00 PM
From: opalapril	Read Replies (2) \| Respond to of 17367

P.S. I have this sinking feeling I will be the last one left on The Death Watch, still holding Xoma shares in my sweaty fist as we enter the 21st century waiting for more people to die and this $%%##&^%^$% trial to come to a close at last.

To: Cacaito who wrote (9319)	3/22/1999 11:01:00 PM
From: aknahow	Read Replies (2) \| Respond to of 17367

Confirmation of what you have said about much higher mortality from St. Mary's, itself. Saving the lives of children with meningococcal disease Meningococcal disease is a major cause of child death in the United Kingdom - the overall mortality rate is ten percent, but up to sixty percent of those with shock may die. Unfortunately, many general hospitals lack the appropriate intensive care facilities or experience of the condition, while often children are deemed too ill to transfer to specialist centres. Now St Mary's Hospital Medical School, in conjunction with the NHS, has initiated a specialist retrieval team programme. The consultant-led retrieval team travels to the general hospital, resuscitates the child, and then takes him or her to the intensive care unit at St Mary's using what is essentially a mobile intensive care unit. This programme has saved the lives of desperately ill children up to 200 miles from London. Because so many children have been treated at a one centre, the Meningococcal Research Unit has been able to do basic research on the inflammatory mechanisms and immune responses involved in the disorder. E-mail: press.office@ic.ac.uk Yes this is dated Oct 97. But one must ask was the 60% mortality figure just there to show what a great job they do with a lower rate?

To: Cacaito who wrote (9319)	3/23/1999 8:49:00 PM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Robert S, please excuse me one mistake, correction to follow. "Protein C, and activated protein C could lead to massive hypercoagulation (the opposite of AIII) same problem of effective dose to near the toxic dose." Protein C is actually used in hypercoagulation states and help disolve clots, this feature is the same of tpa, and AIII (at different levels), and the reason it could be of help in the coagulation fase of DIC (disseminated intravascular coagulation) that is seen in many severe septic patients. It could be a good combination with BPI (if both are proven effective in sepsis). My bias is Bpi.